← Back to patent-cliff list
BRS201
Tier C — Watch / tradeBRS201
The Brigham and Women's Hospital
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Ulcerative colitis, Sclerosing cholangitis
Regional status
US
Phase II
2023-12-12
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BRS201?
Approved indications include: Ulcerative colitis, Sclerosing cholangitis.
When does the BRS201 patent expire?
No public expiry year is available for BRS201 yet; this page updates once verified.
How do I get a quote for BRS201 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02